From: gts (gts_2000@yahoo.com)
Date: Thu Feb 20 2003 - 08:17:30 MST
>> Is it likely to enhance sex drive in normal healthy humans?
Rafal answered: "don't know"
You should know Rafal that improved sex drive is a known side-effect of
many dopamine agonists in humans, as it is also with levodopa. From your
perspective it is listed as a "side-effect." It should not be considered
unlikely by you then that a MAO-B inhibitor like selegiline, which
increases dopamine levels, would also increase sexual activity. The drug
works toward this end in a manner similar to the drug apomorphine
(Uprima), currently available in Europe for erectile dysfunction. Rather
than just working on the plumbing (like Viagra), apomorphine (Uprima)
actually stimulates dopaminergic neurons in the sex centers of the brain
in much the way as does selegiline. Apomorphine may be more selective
for this effect than selegiline, but they both work on the same
principle.
I've already reported one study of this effect of selegiline in rats, in
which the animals enjoyed:
1) improved sexual ability,
2) improved learning ability, and
3) prolonged life-span.
Below is yet more evidence of sexual effects from another animal study:
In this study below, young sexually active selegiline treated rats
enjoyed roughly *DOUBLE* the number of ejaculations compared to the rats
in the control group!
As in the previously mentioned study, they also learned better and lived
longer.
ABSRACT:
Sexually low performing male rats die earlier than their high performing
peers and (-)deprenyl treatment eliminates this difference
Knoll J, Yen TT, Miklya I
Department of Pharmacology,
Semmelweis University of Medicine,
Budapest, Hungary.
Life Sci 1994; 54(15):1047-57
ABSTRACT
Out of 1600 sexually inexperienced 28-week old Wistar-Logan male rats 94
sexually inactive ('low performing', LP) and 99 highly active ('high
performing', HP) rats were selected. The rats were treated from the 8th
month of their life three times a week, subcutaneously, with either 0.9%
NaCl or 0.25 mg/kg (-)deprenyl until they died. Their copulatory
activity was tested once a week and their learning performance was
measured in the shuttle box once in three months. The salt treated LP
rats (n = 44) never displayed ejaculation during their life time, they
were extremely dull in the shuttle box and lived 134.58 2.29 weeks.
Their (-)deprenyl-treated peers (n = 48) became sexually active, their
mating performance was substantially increased and lived 152.54 1.36
weeks, significantly longer than their salt-treated peers and as long as
the salt-treated HP rats. The salt treated HP rats (n = 49) displayed
14.04 0.56 ejaculations during the first 36-week testing period and due
to aging they produced 2.47 0.23 ejaculations between the 73-108th week
of testing. Their learning performance was high. They displayed 78.45
3.01 conditioned avoidance responses (CAR) during the first 36-week
testing period and this dropped to 50.67 2.99 (p < 0.01) during the
73-108th week of testing. They lived 151.24 1.36 weeks, significantly
(p < 0.001) longer than their LP peers. The (-)deprenyl-treated HP rats
(n = 50) were sexually much more active than their salt-treated peers.
They displayed 30.04 0.85 ejaculations during the first 36-week testing
period and 7.40 0.32 ejaculations between the 73-108th week of testing.
Also their learning performance was substantially increased. They
produced 113.98 3.23 CARs during the first 36-week-testing period and
81.68 2.14 CARs during the 73-108th week of testing. They lived 185.30
1.96 weeks, significantly more than their salt-treated peers and out of
the 50 rats 17 lived longer than the estimated technical life span
(TLS).
This archive was generated by hypermail 2.1.5 : Thu Feb 20 2003 - 08:18:44 MST